948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Fuchs, C. S.; Shitara, K.; Di Bartolomeo, M.; Lonardi, S.; Al-Batran, S. E.; Van Cutsem, E.; Ilson, D. H.; Alsina, M.; Chau, I.; Lacy, J.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation
    Journal Article

    Marty, F. M.; Winston, D. J.; Chemaly, R. F.; Mullane, K. M.; Shore, T. B.; Papanicolaou, G. A.; Chittick, G.; Brundage, T. M.; Wilson, C.; Morrison, M. E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Important group differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms in patients with metastatic renal cell carcinoma
    Journal Article

    Cella, D.; Motzer, R. J.; Rini, B. I.; Cappelleri, J. C.; Ramaswamy, K.; Hariharan, S.; Arondekar, B.; Bushmakin, A. G.
    Value in Health (2018)

    Fulltext@MSK | Save
  • A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Monk, B. J.; Kauderer, J. T.; Moxley, K. M.; Bonebrake, A. J.; Dewdney, S. B.; Secord, A. A.; Ueland, F. R.; Johnston, C. M.; Aghajanian, C.
    Gynecologic Oncology (2018)

    Fulltext@MSK | Save
  • A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Journal Article

    Schram, A. M.; Gandhi, L.; Mita, M. M.; Damstrup, L.; Campana, F.; Hidalgo, M.; Grande, E.; Hyman, D. M.; Heist, R. S.
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Tew, W. P.; Sill, M. W.; Walker, J. L.; Secord, A. A.; Bonebrake, A. J.; Schilder, J. M.; Stuckey, A.; Rice, L.; Tewari, K. S.; Aghajanian, C. A.
    Gynecologic Oncology (2018)

    Fulltext@MSK | Save
  • CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes
    Journal Article

    de Lima, M.; Oran, B.; Champlin, R. E.; Papadopoulos, E. B.; Giralt, S. A.; Scott, B. L.; William, B. M.; Hetzer, J.; Laille, E.; Hubbell, B.; more...
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    Journal Article

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Shitara, K.; Doi, T.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Autologous CD19-Targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Journal Article

    Geyer, M. B.; Rivière, I.; Sénéchal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Halton, E.; Lamanna, N.; more...
    Molecular Therapy (2018)

    Fulltext@MSK | Save